A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone.

"Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MAW is a consultant for Boehringer-Ingelheim, Daiichi Sankyo, Forest, Novartis, and Takeda; PS has received grant income from consultancies from Pfizer and Amgen and consultancy fees from Takeda; AJ and AR are no longer employees of Takeda, though, they were during the time the research was conducted; CC is an employee of Takeda."

"Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was sponsored by Takeda Development Center Americas, Inc., Deerfield, IL, USA. High-resolution and color figures as well as drafting or formatting tables for this manuscript were produced by Sam Schmitt of Extenxion Media Group, LLC and Blue Momentum, an Ashfield Company, and were supported by Takeda Development Centers America, Inc."